EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Pharmacokinetics of Depemokimab Delivered by Safety Syringe Device or Autoinjector in Healthy Adults: A Phase 1, Single‐Dose Study

Stein Schalkwijk, Chiara Zecchin, Anusmita Sen, Sei Choi, Kai Wang, Jeff Min, Brian Spears

Clinical Pharmacology in Drug Development · 2025

DOI: 10.1002/cpdd.1506 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Stein Schalkwijk und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology Modelling and Simulation, GSK, London, UK. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This Phase I, randomized, multicenter, open‐label, parallel‐group, single‐dose study assessed the relative bioavailability of the anti–interleukin‐5 antibody depemokimab (100 mg) when administered subcutaneously via either a safety syringe device (SSD) or an autoinjector (AI). Healthy adult participants were randomized I:I to SSD or AI treatment arms and I:I:I to the injection site (upper arm, abdomen, or thigh). Participants were followed up for 30 weeks; blood samples were collected for pharmacokinetic (PK) assessment before dosing on Day 1 and up to Week 26. Depemokimab concentration profile as measured by plasma maximum concentration (C max ), the area under the concentration–time curve from time zero extrapolated to infinity (AUC 0‐inf ), PK parameters, immunogenicity, and safety were assessed. Overall, 140 participants were enrolled (n = 70 per arm). Mean plasma concentration‐time profiles of depemokimab were similar in both treatment arms, regardless of the injection site, adjusted geometric mean AI:SSD ratios for C max and AUC 0‐inf were 1.03 and 1.03, respectively, with all 90% confidence intervals within the bioequivalence bounds of 0.80‐1.25. PK parameters were comparable across treatment arms. Treatment‐related adverse events were reported in 19% of SSD and 20% of AI participants, with headache being the most common across both arms; no adverse events led to study withdrawal. These results support the use of either SSD or AI for subcutaneous administration of depemokimab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedHumansMaleFemaleAdultInjections, SubcutaneousSyringesMiddle AgedArea Under CurveYoung AdultHealthy VolunteersBiological AvailabilityTherapeutic Equivalency

Stichwörter der Autor:innen

biologicsdepemokimabdrug metabolismpharmacokineticsself‐administration

Substanzen

Antibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Clinical Pharmacology Modelling and Simulation, GSK, London, UK.
  • Clinical Pharmacology Modelling and Simulation, GSK, Stevenage, Hertfordshire, UK.
  • Biostatistics, GSK, Bengaluru, India.
  • Global Clinical Development, GSK, Ottawa, Canada.
  • Biomarker and Bioanalytical Platform, GSK, Collegeville, PA, USA.
  • Clinical Research Respiratory, GSK, Waltham, MA, USA.

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Schalkwijk, S., Zecchin, C., Sen, A., Choi, S., Wang, K., Min, J., & Spears, B. (2025). Pharmacokinetics of Depemokimab Delivered by Safety Syringe Device or Autoinjector in Healthy Adults: A Phase 1, Single‐Dose Study. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1506

Vancouver

Schalkwijk S, Zecchin C, Sen A, Choi S, Wang K, Min J, et al. Pharmacokinetics of Depemokimab Delivered by Safety Syringe Device or Autoinjector in Healthy Adults: A Phase 1, Single‐Dose Study. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1506

BibTeX
@article{Schalkwijk2025,
  author = {Schalkwijk, Stein and Zecchin, Chiara and Sen, Anusmita and Choi, Sei and Wang, Kai and Min, Jeff and Spears, Brian},
  title = {Pharmacokinetics of Depemokimab Delivered by Safety Syringe Device or Autoinjector in Healthy Adults: A Phase 1, Single‐Dose Study},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2025},
  doi = {10.1002/cpdd.1506}
}
Kostenlos starten →